Merck to pay $58m in settlement over rofecoxib advertisingBMJ 2008; 336 doi: https://doi.org/10.1136/bmj.39591.705231.DB (Published 29 May 2008) Cite this as: BMJ 2008;336:1208
- Fred Charatan
Merck & Company has agreed to pay $58m (£29m; €37m) to settle allegations that advertising for its analgesic rofecoxib (Vioxx) played down potential health risks.
The civil settlement ends investigations by 29 US states and the District of Columbia into Merck’s previous advertising practices for the drug. Tom Corbett, attorney general of Pennsylvania, said that the agreement is the largest in a multi-state consumer protection case involving drugs.
Mr Corbett said that in 1999 Merck had launched “an aggressive and deceptive advertising …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial